Literature DB >> 21622593

Community walking can be assessed using a 10-metre timed walk test.

J C E Kempen1, V de Groot, D L Knol, C H Polman, G J Lankhorst, H Beckerman.   

Abstract

BACKGROUND: A decline in mobility is a common feature of multiple sclerosis (MS). Community walking scales are used to categorize patients in their ability to move independently. The first purpose of this study was to determine which specific gait speed corresponded with the categories of the Modified Functional Walking Categories (MFWC). The second purpose was to determine the Minimally Important Change (MIC) in absolute gait speed using the MFWC and Expanded Disability Status Scale (EDSS) as external criteria.
METHOD: MS patients were measured six times in 6 years. Gait velocity was measured with the 10-metre timed walk test (10-m TWT), the severity of MS was determined with the EDSS, and community walking was assessed with the MFWC. For each category of the MFWC, Receiver Operating Characteristic (ROC) curves were used to find the best possible cut-off point on the 10-m TWT. The MIC in absolute gait speed was determined using a change of one category on the MFWC or one point on the EDSS.
RESULTS: A strong relationship was found between gait speed and the MFWC; all areas under the ROC curves (AUCs) were between 0.74 and 0.86. The MIC in absolute gait speed could not be determined, because the AUCs were below the threshold of 0.70 and changes in gait speed were small.
CONCLUSIONS: Gait speed is related to community walking, but an MIC in absolute gait speed could not be determined using a minimally important change on the MFWC or the EDSS as external criteria.

Entities:  

Mesh:

Year:  2011        PMID: 21622593     DOI: 10.1177/1352458511403641

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  14 in total

1.  Machine learning classification of multiple sclerosis patients based on raw data from an instrumented walkway.

Authors:  Wenting Hu; Owen Combden; Xianta Jiang; Syamala Buragadda; Caitlin J Newell; Maria C Williams; Amber L Critch; Michelle Ploughman
Journal:  Biomed Eng Online       Date:  2022-03-30       Impact factor: 2.819

2.  Improving Detection of Change in Motor Functioning in Multiple Sclerosis Using Video-Assisted Composite Measures.

Authors:  Ka-Hoo Lam; Caspar E P van Munster; Marcus D'Souza; Saskia Steinheimer; Christian P Kamm; Jessica Burggraaff; Matthew Johnson; Yordan Zaykov; Jonas Dorn; Frank Dahlke; Ludwig Kappos; Joep Killestein; Bernard Uitdehaag
Journal:  Int J MS Care       Date:  2022-06-20

Review 3.  Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.

Authors:  Graziella Filippini; Silvia Minozzi; Francesca Borrelli; Michela Cinquini; Kerry Dwan
Journal:  Cochrane Database Syst Rev       Date:  2022-05-05

4.  Objectively assessed physiological, physical, and cognitive function along with patient-reported outcomes during the first 2 years of Alemtuzumab treatment in multiple sclerosis: a prospective observational study.

Authors:  Lars G Hvid; Egon Stenager; Ulrik Dalgas
Journal:  J Neurol       Date:  2022-04-28       Impact factor: 6.682

5.  Dissociated functional connectivity profiles for motor and attention deficits in acute right-hemisphere stroke.

Authors:  Antonello Baldassarre; Lenny Ramsey; Jennifer Rengachary; Kristi Zinn; Joshua S Siegel; Nicholas V Metcalf; Michael J Strube; Abraham Z Snyder; Maurizio Corbetta; Gordon L Shulman
Journal:  Brain       Date:  2016-05-25       Impact factor: 13.501

Review 6.  Outcome Measures in Clinical Trials for Multiple Sclerosis.

Authors:  Caspar E P van Munster; Bernard M J Uitdehaag
Journal:  CNS Drugs       Date:  2017-03       Impact factor: 5.749

7.  Intensive Multimodal Training to Improve Gait Resistance, Mobility, Balance and Cognitive Function in Persons With Multiple Sclerosis: A Pilot Randomized Controlled Trial.

Authors:  Johanna Jonsdottir; Elisa Gervasoni; Thomas Bowman; Rita Bertoni; Eleonora Tavazzi; Marco Rovaris; Davide Cattaneo
Journal:  Front Neurol       Date:  2018-09-28       Impact factor: 4.003

8.  Factors for lower walking speed in persons with multiple sclerosis.

Authors:  Leandro Alberto Calazans Nogueira; Luciano Teixeira Dos Santos; Pollyane Galinari Sabino; Regina Maria Papais Alvarenga; Luiz Claudio Santos Thuler
Journal:  Mult Scler Int       Date:  2013-03-31

9.  Sustained-release fampridine (4-aminopyridine) in multiple sclerosis: efficacy and impact on motor function.

Authors:  Meheroz H Rabadi; Kimberly Kreymborg; Andrea S Vincent
Journal:  Drugs R D       Date:  2013-09

10.  Assessing Walking Ability in People with HTLV-1-Associated Myelopathy Using the 10 Meter Timed Walk and the 6 Minute Walk Test.

Authors:  Adine Adonis; Graham P Taylor
Journal:  PLoS One       Date:  2016-06-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.